LifeSciences BC > Member Announcements > Welcome to Meet with WAT Med at Medica Germany

Welcome to Meet with WAT Med at Medica Germany

VANCOUVER, British Columbia, Oct. 31, 2018 /PRNewswire/ — WAT Medical would go back 2018 Medica Show to exhibit innovative wearable technologies EmeTerm, an anti-vomiting wrist band, and HeadaTerm, an anti-migraine head patch.

WAT Medical is a company located in Canada that develops safe, effective, and user-friendly wearable medical devices. It focuses on chronic and functional diseases and conditions. Its technologies use targeted neuromodulation to regulate specic nerve activities. The process is patient-oriented, with xed parameters for individual conditions, and features excellent usability. Consumer will receive the specic type of therapy that they need. The wearable design allows the devices to be extremely portable and easy to use at all times and places.

EmeTerm is an anti-nausea wristband that uses precise transcutaneous electrical nerve stimulation (TENS) to stop the vomiting center of the brain from sending vomiting signals to the stomach. This function targets all kinds of nausea related vomiting, including travel sickness, morning sickness, virtual reality, chemotherapy, and surgical operations.

The device provides innovative interface and usability, offering water resistance, magnetic charging port, advanced electrode that does not require conduction gel, and replaceable hypoallergenic wrist straps.

HeadaTerm is an anti-migraine head patch that also uses precise transcutaneous electrical nerve stimulation (TENS). It targets the pain receptors in the brain, and stimulates release of various neurotransmitters that are involved relieving pain and promoting pleasure. The device is suitable for all ages, and can be used to treat and/or prevent all types of primary headaches, including migraine, cluster, and tension.

HeadaTerm is a disposable device that offers 21 treatments, with each treatment lasting 20 minutes. This feature allows the device to be much more affordable and portable. HeadaTerm comes with a built-in battery, and offers replaceable adhesive gels. HeadaTerm, once implemented into the healthcare system, would be an extremely cost-effective solution for patients not only for its low price, but also for the time and resources saved from visiting clinics and hospitals.

WAT Med offers these two wearable devices that target chronic and functional disease such as nausea, vomiting and headaches. The common remedy people seek for nausea and migraine are medications, which often comes with debilitating side-effects. Our goal is to improve patients’ quality of life through these self-care devices and avoid the side effects of the medications.

WAT Med continues to develop innovative healthcare solutions. Future projects include closedloop data that collect user’s physical information for health management, as well as research in vision therapy that involves improving vision acuity by stimulating targeted nerve nuclei.

Dr. Eric Topol, a globally recognized cardiologist, has commented in his book, the Creative Destruction of Medicine, that digital technologies will transform the landscape of healthcare. Innovative medical technologies are on their way to making breakthroughs in the future, offering more precise and advanced treatment along with, or even in place of, traditional medicine.

 

2017

2018

2019

EmeTerm

 CE

FDA, HC, TGA, IMOH, CFDA

KFDA,  JFDA

HeadaTerm

WAT Med plans to expand its healthcare network to pharmacies, clinics, cruise lines, gift shops, supermarkets, and online stores. By 2018, EmeTerm and HeadaTerm have not only received FDA(USA) certication, but also CE(Europe), HC(Canada), TGA(Australia), and IMOH(Israel). The devices can be found in over 20 different countries worldwide.
Next week, the technologies are going to be brought to the largest health care show Medica in Dusseldorf, Germany. Stand Hall 16/F46.

References:
1. https://www.watmedical.com/about/ 2. https://www.prnewswire.com/news­releases/headaterm­tm­the­cost­would­not­add­pain­to­migraine­patients­ 300495929.html 3. https://www.mddionline.com/will­tracker­aesthetics­lead­anti­nausea­device­bonanza